Psioxus Therapeutics Ltd., of Oxford, U.K., said it started a study to test its oncolytic virus candidate, enadenotucirev, in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with carcinomas. The SPICE (Study of Pembrolizumab In Combination with Enadenotucirev) trial aims to assess the ability of enadenotucirev to reverse resistance to checkpoint inhibitors for certain tumor types, including metastatic colorectal cancer. The trial is expected to run until 2017.